Remove 2020 Remove Pharmacology Remove Side effects
article thumbnail

Tackling the complex development landscape of pain medicines

European Pharmaceutical Review

The current medications (opioid and non-opioid) often force the patients to make an unfortunate choice between efficacy and debilitating side effects, leading to a cycling through multiple different therapies and suboptimal treatment response. The present unmet needs within chronic pain are not met with opioid therapies. Internet] NIH.

Medicine 102
article thumbnail

The potential of virtual reality-based therapy for serious mental disorders

Pharmaceutical Technology

Anti-psychotics come with the risk of side effects such as drowsiness, agitation and blurred vision, so virtual reality (VR) technologies that can enhance recovery without anti-psychotics are an attractive option. In 2020, OxfordVR secured a $12.5m Series A funding from Optum Ventures, supported by Luminous Ventures.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Role of Certified Pharmaceutical Representatives in the Shifting Sales Landscape

Pharmaceutical Representative Training

Preventing Misuse: Strict regulations are required to stop the improper use and abuse of drugs, especially those that have strong side effects or the potential to become addictive. Case Summary: In 2020, this company agreed to pay $678 million to settle allegations that it violated the False Claims Act by paying kickbacks to doctors.

Sales 52
article thumbnail

Top-10 ways for Pharma to leverage AI according to…AI

Impetus Digital

In theory, this will allow for highly tailored, personalized therapy plans with superior efficacy and minimal side effects. In 2020, McKinsey estimated that over the next 3–5 years, the average top-20 Big Pharma company could unlock over $300 million a year by adopting advanced RWE analytics across its value chain.

Pharma 95
article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

While new positive clinical data with anti-Abeta mAbs signal tremendous advancement and proof‑of-concept for the whole field, it is believed that the observed effects could still be improved and optimised in terms of greater clinical benefits, lower side effects and enhanced treatment convenience.